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Impact of annual dosing with ivermectin on
progression of onchocercal visual field loss*
S.N. Cousens,1 A. Cassels-Brown,2 1. Murdoch,2 O.E. Babalola,3 D. Jatau,4
N.D.E. Alexander,2 J.E. Evans,2 P. Danboyi,4 A. Abiose,4 & B.R. Jones2
Reported are the results of a randomized, double-masked, placebo-controlled trial of annual ivermectin
dosing in 34 rural communities, Kaduna State, northern Nigeria, where guinea savanna onchocerciasis is
mesoendemic. A total of 939 individuals underwent Friedmann field analysis at the first examination and saw
at least 19 spots in at least one eye. Of these, 636 (68%) completed a subsequent Friedmann field analysis
2-3 years later. The adjusted incidence rate ratio for the ivermectin group versus the placebo group was 0.64
(95% confidence interval (Cl): 0.42-0.98). There was some evidence that the impact of ivermectin was
greatest among those who had received one dose of ivermectin. The majority of the deteriorations occurred
in eyes that gave evidence of optic atrophy at the first examination. An analysis restricted to individuals with
optic atrophy at baseline indicated a reduction of 45% in the incidence of visual field deterioration in the
ivermectin group (95% Cl: 8-67%). Previous findings have shown that ivermectin has an impact on the
incidence of optic atrophy. Our results indicate, for the first time, that ivermectin has a substantial impact on
the progression of visual field loss among those with pre-existing optic atrophy.
Introduction
Onchocerciasis is one of the major causes of blind-
ness. Two commonly reported ocular sequelae of
onchocercal infection are optic nerve disease and
chorioretinitis (1), both of which can cause dramatic
reductions in the peripheral visual field, leaving only
a small island of central vision (2). In such cases
visual acuity may be largely unaffected until a late
stage of the disease process.
Ivermectin is now the drug of choice for the
treatment of onchocerciasis, and annual dosing with
it substantially reduces the incidence of optic nerve
disease among infected individuals (3) and produces
beneficial effects on other onchocercal eye lesions,
including punctate keratitis (4) and iridocyclitis
(5). Less is known, however, about the impact of
ivermectin on visual function loss and, in particular,
visual field loss. In this article we report the effect of
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annual dosing with the drug on the progressive de-
terioration of visual field loss in northern Nigeria.
Methods
The population studied and methods used in the
trial have been described previously (3, 6), Briefly,
a randomized, double-masked, placebo-controlled
trial of ivermectin was conducted in 34 rural com-
munities that were mesoendemic for guinea savanna
onchocerciasis, in Kaduna State, northern Nigeria.
A census was carried out on the communities and
demographic data and pertinent information, such
as previous use of diethylcarbamazine (DEC), was
collected.
Skin-snips were taken from villagers aged -5
years, who were then registered for inclusion in the
trial and randomly assigned at the individual level
using a blocked design to receive ivermectin or pla-
cebo. Annual dosing with ivermectin/placebo was
performed over a 3-year period. At the fourth an-
nual round, all villagers received ivermectin. Stand-
ard exclusion criteria were applied at each dosing.
The trial participants underwent ophthalmic ex-
amination prior to the first, third, and fourth annual
dosings. At each examination all villages were vis-
ited, and registered individuals were asked to report
to a central location in their village. Each patient was
screened for signs of optic nerve disease by a team of
ophthalmic nurses who had received intensive
training from two ophthalmologists (LM., O.E.B.)
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before the start of the fieldwork. The screening ex-
amination consisted of a series of visual function
tests (including visual acuity, peripheral visual field
assessment by counting fingers in all four quadrants,
paracentral visual field assessment using a variety of
tests, colour vision, and a test for red desaturation),
applanation tonometry, examination of pupillary
light response, and undilated fundoscopy to assess
optic disc colour and cup: disc ratio. Individuals who
failed the screening examination were referred to an
ophthalmologist; the referral criteria included
reduced visual acuity that did not improve to 6/9
with pinhole, failure of any of the other visual
function tests, and intraocular pressure ¢'2.80 kPa
(:21 mmHg), an abnormal pupillary light response,
suspicion of disc pallor or a cup: disc ratio >0.5.
In addition, individuals belonging to a computer-
generated random sample of the trial population
were also referred to an ophthalmologist, regardless
of the outcome of the screening examination.
The ophthalmologist examined the referred pa-
tients in a mobile clinic equipped with a slit-lamp
biomicroscope, applanation tonometer, and retinal
camera. After the patient's pupillary light response
had been checked, the individual concerned re-
turned to the ophthalmic nurse for pupillary dilation,
dark adaptation, and Friedmann mark I visual field
analysis. Topical mydriatics (cyclopentolate hydro-
chloride (1% (w/v)) and phenylephrine hydrochlo-
ride (10% (w/v)) were instilled until the pupils were
maximally dilated and nonreactive to light.
The Friedmann mark I Analyser is a form of
static perimetry in which the central 250 of visual
field is measured at a distance of 33cm. A total of
46 illuminated targets (generated by electronic flash
and modified by specified neutral density filters) are
presented to the patient in patterns of two, three, or
four at a time. The patient indicates how many points
or "spots" were seen and localizes their position; the
points are then recorded on a standard form with
the corresponding filter value at which they were
seen. This form of field analysis is less sensitive to
some early visual field defects than some other
methods, such as computer-assisted or Goldmann
(7). The Friedmann Analyser performs relatively
well at detecting visual fields with a central island or
central defects (8). Since onchocercal defects essen-
tially constrict the visual field with preservation of a
central island (2), the Friedmann Analyser is suit-
able for use in onchocercal populations. The mark II
Friedmann Analyser tests 98 rather than 46 points,
but the small advantage that this would provide (9)
was not considered sufficient to warrant the addi-
tional test time required, nor the increased potential
for machine failure. Field loss, as measured by the
Friedmann Analyser, may manifest itself as either a
decrease in sensitivity or absolute loss of stimulus
perception. In this article, we consider only absolute
loss of stimulus perception.
The Friedmann field analyses were performed
in rooms darkened with blackout material. The pa-
tient sat at the appropriate height and used the palm
of one hand to occlude one eye. The nurse perform-
ing the analysis explained the test in Hausa, the most
widely spoken language in the area, and the macular
threshold was determined. Individuals were encour-
aged to maintain central fixation and were observed
while the test was run at 0.4dB below the macular
threshold, at a further 0.4dB below this value, and
finally at maximum brightness, when necessary.
The results of the test were noted on the standard
Friedmann analysis form. At the first examination,
the Friedmann test for each patient was performed
by the ophthalmic nurse who had performed the
screening examination; at the subsequent examina-
tions, all Friedmann field tests were performed by
one ophthalmic nurse.
Following Friedmann field analysis, the patient
returned to the mobile clinic. At the second and
third examinations the ophthalmologist compared
the Friedmann field result with any previous results
using a quadrant-by-quadrant summary. If there
were major incongruities, the Friedmann analysis
was repeated. Patients then underwent posterior
segment examination with slit-lamp biomicroscopy,
direct and indirect ophthalmoscopy, and fundus
fluoroscein angiography. Upon completion of the
examination, patients were dosed with ivermectin/
placebo by a general physician or rural health officer.
In order to identify individuals with visual field
deterioration during follow-up, an initial analysis
of Friedmann field changes was performed. The
number of individuals showing an improvement was
compared with the number showing a deterioration
for each designated cut-off point (e.g. ¢12 spots
lost or gained). We assumed that most apparent
improvements were probably due to measurement
variations rather than true improvements, and in or-
der to maintain as high a specificity as possible, we
chose as cut-off point the minimum number of spots
lost/gained that produced a ratio of deteriorations:
improvements :10: 1. The cut-off point thus identi-
fied was a change of >19 spots seen/not seen in one
eye (92 individuals with deteriorations versus 8 with
improvements, 4 of whom received ivermectin). Be-
low, "visual field deterioration" refers to the abso-
lute loss of :19 of the 46 Friedmann spots in one eye
during the period of follow-up. Only changes be-
tween the first and last examination are considered
here.
Data were double-entered on microcomputers
and analysed using SAS/PC and EGRET software
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packages. Poisson regression was used to estimate
the incidence ratios using person-time of follow-up
as the denominator. The homogeneity of the rate
ratio (ivermectin versus placebo) across different
values of other variables was tested by fitting an
interaction term and examining the likelihood ratio
statistic (10).
Results
Follow-up
At the first examination and dosing, 939 individuals
registered in the trial underwent Friedmann field
analysis and saw >19 spots in at least one eye (and
thus were at risk of deterioration according to the
definition chosen). Of these individuals, 636 (68%)
completed a Friedmann field analysis at one or more
of the follow-up examinations. The mean period
of follow-up was 28.3 months (range, 17.0-38.0
months). Follow-up was similar in the two treatment
groups (ivermectin = 314 individuals (66%), mean
= 28.3 months; placebo = 322 individuals (69%),
mean = 28.2 months). The rate of follow-up was not
associated with age (P = 0.19), sex (P = 0.18), or
microfilarial load at baseline (P = 0.18). Rates of
follow-up were higher among individuals in the ran-
dom sample (75% versus 63%, P < 0.001) and those
who had reported having taken DEC (77% versus
60%, P < 0.001). Follow-up also varied according to
the individual's Friedmann field status at baseline,
being highest among those who had missed some,
but not all spots in their worse eye (75%), compared
with 64% among those who had seen all 46 spots
and 68% among those who had missed them all
(P = 0.04).
Baseline characteristics of the treatment
groups
Table 1 shows the distribution of individuals and
follow-up time by treatment group according to age
at census, sex, microfilarial load at baseline, reported
history of DEC consumption, membership of the
random sample, and the results of the Friedmann
field analysis at baseline. There were no major differ-
ences between the two treatment groups with regard
to any of these variables. All age groups were repre-
sented, though the number of individuals aged over
64 years was comparatively small. There were more
males (55%) than females. The majority of individu-
als (71%) were skin-snip positive at baseline, 31%
having loads >10 microfilarae (mf) per mg; very few,
however, had loads >SOmf per mg (6%). About half
(52%) reported having used DEC. A total of 270
individuals (42%) were from the random sample;
348 individuals (55%) saw all Friedmann spots in
both eyes at baseline, while 67 individuals (11%)
missed all 46 spots in one eye.
Treatment with ivermectin/placebo
Of the 636 individuals who completed follow-up, 255
(40%) underwent Friedmann field analysis only
twice (at the start and end of follow-up), 286 (45%)
three times, and 95 (15%) on four occasions. The
mean number of analyses performed was similar in
the two treatment groups (ivermectin = 2.73; pla-
cebo = 2.76). Over the period of follow-up, 273 indi-
viduals (43%) received three doses of ivermectin/
placebo between their first and final examinations,
287 (45%) two doses, 60 (9%) one dose, and 16 (3%)
were excluded at each dosing round and thus were
never dosed during the period of follow-up. The dis-
tribution of the number of doses received by indi-
viduals with follow-up in the two treatment groups
was similar (Table 1).
Visual field deteriorations
A total of 92 individuals (14%) had "lost" at least 19
spots in one eye between the baseline and follow-up
examinations. Of these individuals 19 had suffered
bilateral deteriorations, while the other 73 had
deteriorated unilaterally. Of these 92 individuals, 34
(37%) were in the ivermectin group and 58 (63%)
in the placebo group (Table 1), giving an incidence
ratio of 0.60 (95% confidence interval (CI) = 0.39-
0.92; P = 0.02) in the ivermectin group relative to the
placebo group.
The incidence of deteriorations tended to in-
crease with age (P < 0.001), although there were
relatively few instances among those aged 55-64
years, and was higher among males than females
(P = 0.02) in both treatment groups (Table 1).
Deteriorations appeared to be commoner among the
skin-snip positive, particularly in the placebo group
(P = 0.03). There was no evidence that reported
DEC consumption prior to the initial examination
was associated with the incidence of visual field
deteriorations during the period of follow-up (P =
0.15). Deteriorations among members of the random
sample (who had not necessarily failed the screening
examination) were much less likely than among
those who were not members of this sample (and
who had failed the screening examination; P <
0.001). Visual field status at baseline was associated
with rate of deterioration (P < 0.001), deteriorations
tending to be more frequent among individuals who
had missed spots at baseline. Although the incidence
of deteriorations appeared to increase with the num-
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Table 1: Baseline characteristics, number of Friedmann field analyses undergone, number of doses of ivermectin/
placebo received, and incidence of deteriorations in Friedmann visual field analysis, by treatment group, among
the study subjectsa
Ivermectin group Placebo group
No. with Incidence (per 100 No. with Incidence (per 100
n deterioration person-years) n deterioration person-years)
Age (years)
5-14 24 1 1.80 23 0 0
15-24 45 1 0.96 38 0 0
25-34 67 4 2.52 68 14 8.88
35-44 76 9 4.92 88 18 8.76
45-54 57 11 8.28 53 13 10.20
55-64 29 3 4.56 36 3 3.60
>65 16 5 12.60 16 10 25.20
Sex
Male 172 24 5.88 176 38 9.12
Female 142 10 3.00 146 20 5.88
Microfilarial load
Negative 94 7 3.24 89 8 3.72
0.1-10.0 119 16 5.64 131 31 9.96
10.1-50.0 73 8 4.68 82 17 9.00
50.1-100.0 20 3 6.12 12 2 6.72
>100 2 0 0 4 0 0
Unknown 6 0 0 4 0 0
DECb taken in past
No 156 14 3.96 149 22 6.48
Yes 155 20 5.40 173 36 8.64
Unknown 3 0 0 0 0 Undefined
Random sample
No 174 31 7.56 192 48 10.56
Yes 140 3 0.96 130 10 3.36
No. of spots missed in better eye at baseline
0 229 17 3.12 245 37 6.48
1-10 43 12 11.64 36 14 16.56
11-20 24 4 7.32 28 6 9.12
>21 18 1 2.16 10 1 4.32
No. of spots missed in worse eye at baseline
0 169 6 1.56 179 17 4.08
1-10 38 10 10.92 51 16 13.44
11-20 28 5 7.44 21 4 7.68
21-45 43 6 5.76 40 9 9.60
All 36 7 7.92 31 12 16.20
No. of Friedmann analyses performed
2 133 10 3.64 122 16 6.55
3 132 15 4.48 154 31 7.91
4 49 9 6.89 46 11 9.00
No. of doses of ivermectin/placebo received
0 7 1 6.72 9 1 5.28
1 36 1 1.32 24 8 15.00
2 137 9 3.12 150 23 7.44
3 134 23 6.36 139 26 6.96
Total 314 34 4.56 322 58 7.68
a A subsample was alsb examined 7-14 days after first dosing, so that some individuals underwent four Friedmann field analyses.
b DEC: diethylcarbamazine.
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ber of Friedmann analyses performed, this trend was
not statistically significant (P = 0.12). None of these
factors appeared to confound the association be-
tween treatment group and incidence of visual field
deterioration.
When each variable was entered individually
into a Poisson regression model containing a term
for treatment group, the rate ratio for ivermectin
versus placebo varied between 0.59 (number of spots
missed by worse eye at baseline) and 0.63 (member-
ship of random sample). The impact of ivermectin
could vary with age (rate ratio = 0.47, <45 years;
rate ratio = 0.93, 45-64 years; rate ratio = 0.50, >65
years), but this variation was not statistically signifi-
cant (P = 0.35). Also, there was no evidence that the
impact of ivermectin on the incidence of visual field
deteriorations varied with any of the following: sex
(P = 0.50); microfilarial load (P = 0.84); DEC (P =
0.92); random sample membership (P = 0.14); visual
field status at baseline (P = 0.70); and number of
Friedmann field analyses performed (P = 0.84).
The incidence of visual field deterioration
was not associated with the number of doses of
ivermectin/placebo received (P > 0.50; Table 1).
However, when individuals who had not received
any doses of ivermectin/placebo were excluded there
was some evidence that the impact of ivermectin
varied according to the number of doses received,
the impact appearing to be greater among those re-
ceiving one or two doses of ivermectin/placebo than
among those receiving three doses (rate ratios: 0.09,
0.42 and 0.92, resp.; P = 0.02).
A Poisson regression model was fitted to esti-
mate the impact of ivermectin on the incidence of
visual field deteriorations, adjusting for age, sex,
microfilarial load, reported use of DEC, membership
of the random sample, visual field status at baseline
(worse eye), number of Friedmann field analyses
performed, and number of doses of ivermectin pla-
cebo received. Treatment with ivermectin was asso-
ciated with a 36% reduction in the incidence of
visual field deterioration (incidence rate ratio = 0.64;
95% CI = 0.42-0.98; P = 0.04).
To investigate the etiology of the observed
deteriorations, we reviewed the records of all 92
individuals with visual field loss to determine
the prevalence among them of media opacities,
chorioretinal, and optic nerve pathologies at the end
of follow-up. A total of 24 individuals had evidence
of media opacities, mostly in the lens, that could
have restricted visual function (13 ivermectin, 11 pla-
cebo). Of those individuals, 21 also had evidence of
optic nerve and/or chorioretinal pathology.
The distribution of optic nerve and choriore-
tinal disease among the 92 individuals with visual
field loss is shown in Table 2. More than 90% had
Table 2: Distribution of optic nerve and retinal patho-
logies at the end of follow-up among 92 individuals
with visual field deteriorations, by treatment group
No. of individuals
Ivermectin Placebo
Pathology group group Total
Optic nerve only 15 (44)a 24 (41) 39 (42)
Retina only 1 (3) 0 (0) 1 (1)
Optic nerve and retina 14 (41) 33 (57) 47 (51)
Neither pathology 4 (11) 1 (2) 5 (5)
Total 34 (100) 58 (100) 92 (100)
a Figures in parentheses are percentages.
clinical evidence of optic nerve pathology, while just
over half had clinical evidence of chorioretinal pa-
thology. More than 40% had optic nerve pathol-
ogy in the absence of chorioretinal pathology, while
only one individual had chorioretinal pathology in
the absence of optic nerve pathology.
Discussion
Our results suggest that annual dosing with
ivermectin reduces by 36% the occurrence of visual
field deterioration, which is similar to our previous
finding that such dosing reduces the incidence of
optic nerve disease by about 35% (3).
This similarity is, perhaps, not surprising since
optic nerve disease typically results in visual field
loss. Our definition of an incident case of optic nerve
disease was an individual with one or both eyes
having onset of optic disc pallor associated with a
deterioration in visual function and/or pupillary light
response (these cases therefore constitute cases of
optic atrophy). One approach to identifying visual
function deterioration is Friedmann field analysis.
Thus, it is therefore plausible that both of these out-
come measures reflect the same deteriorations, in
the same eyes, in the same individuals. This was,
however, not the case. Of the 92 individuals we iden-
tified with visual field deterioration, only 14 (15%)
were considered to have suffered onset of optic
nerve disease (optic atrophy) during the follow-up
period. Furthermore, among these 92 individuals,
111 eyes were identified as having suffered visual
field deterioration, and of the latter eyes, only 7
(6%) had developed optic nerve disease as defined
above. The apparent inconsistency between the data
for individuals and those for eyes arises because
some individuals experienced onset of optic atrophy
in one eye and visual field deterioration in the other.
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The majority of the 111 eyes with visual field
deterioration (75%) already had evidence of optic
atrophy at the baseline examination. Of the 13
random sample individuals with deteriorations, 12
(92%) failed the nurse's screening examination at
baseline. The one individual who was not identified
at baseline suffered a traumatic cataract during
follow-up. Thus, while our previous findings (3)
revealed that ivermectin had an impact on the inci-
dence of optic atrophy, our present results suggest
that it has also an impact on the progression of pre-
existing disease.
An analysis restricted to individuals with optic
atrophy at baseline confirms the above impression
(Table 3). Among such individuals ivermectin was
associated with a 52% reduction in the incidence of
visual field deteriorations (P = 0.004). There was no
strong evidence to suggest that the impact varied
with the number of doses received (1 dose, rate
ratio = 0.27; 2 doses, rate ratio = 0.38; 3 doses, rate
ratio = 0.63; P = 0.24). After adjustment for age,
sex, microfilarial load at baseline, and visual field in
the worse eye, the estimated reduction in the inci-
dence of visual field loss in those receiving ivermec-
tin was 45% (95% CI = 8-67%).
Our data indicate that optic nerve pathology,
alone or in combination with chorioretinal pathol-
ogy, is an important cause of visual field loss in the
study population; chorioretinal pathology in the ab-
sence of optic nerve pathology does not appear to
be important in this respect. This finding should,
however, be interpreted with caution. The original
ophthalmic nurses' screening examination, which
identified individuals (other than those in the ran-
dom sample) for Friedmann field analysis, was de-
signed to identify those with optic nerve disease
rather than chorioretinal pathology. Individuals with
the latter pathology, in the absence of visual function
defects at first examination, will in general have
been excluded from our sample; however, those with
chorioretinal pathology and visual function defects
were included.
We have previously reported that the impact of
ivermectin on the incidence of optic nerve disease
Table 3: Incidence of visual field deterioration in indi-
viduals with optic nerve disease at baseline
Ivermectin Placebo
group group
No. of individuals 118 109
Person-months of follow-up 3421 3100
No. of deteriorations 24 45
Rate ratio for ivermectin versus placebo 0.48 (0.29, 0.79)a
a Figures in parentheses are the 95% confidence interval.
appears to be largely confined to individuals with
microfilarial loads >lOmf per mg. The incidence of
visual field deterioration by microfilarial load shown
in Table 1 suggests that ivermectin has little or no
impact on such deterioration among skin-snip-
negative individuals (rate ratio = 0.85), but may do
so among those with loads <lOmf per mg. In Sierra
Leone this threshold density had previously been
suggested as being necessary for the occurrence of
acute skin changes (11). Among individuals with
loads -10mf per mg or >lOmf per mg, ivermectin
reduced by 43% the rate of visual field deterioration.
Such an interpretation of the data should be treated
very cautiously, however, since small changes in
the values could radically alter the observed pat-
tern; had we, for example, observed two fewer
deteriorations in skin-snip-negative individuals re-
ceiving ivermectin, the rate ratio among such
individuals would have been 0.61. There was no sta-
tistically significant interaction between the impact
of ivermectin and microfilarial load.
Our results contain two apparent anomalies
which may be related. First, we detected only six
individuals aged 55-64 years with visual field
deteriorations; in view of the pattern of deterio-
rations in the other age groups, three or four times as
many might have been expected. We have no expla-
nation for this shortfall. Second, the impact of a sin-
gle dose of ivermectin appears to be greater than
that of two or three doses.
The number of doses of ivermectin/placebo
received was associated with age and sex - older
individuals tending to receive more doses (P <
0.001) and 51% of males receiving all three doses
compared with only 32% of women (P < 0.001). The
number of doses received did not appear to vary
with initial microfilarial load - 89% of skin-snip-
negative individuals receiving two or three doses of
ivermectin/placebo compared with 88% of skin-snip
positives. The more doses of ivermectin/placebo
received, the more likely the individual reported
having used DEC (P < 0.0001), the less likely the
individual was included in the random sample (P =
0.001), and the less likely the individual was to have
seen all spots at baseline (P = 0.005).
We did not skin-snip all individuals annually,
since this procedure appeared to reduce participa-
tion in the trial, and we aimed to achieve the highest
level of ophthalmic follow-up possible. It is highly
probable, however, that the first dose of ivermectin
produced the greatest reduction in microfilarial load,
with subsequent doses producing smaller reductions,
as observed in other trials (12-15). In addition, Alley
et al. (15) have reported that microfilarial loads can
remain at around half their pre-treatment level for
up to 4 years after a single dose of ivermectin. If the
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rate of visual field deterioration is associated with
microfilarial load, over a 3-year period a single dose
might be almost as effective as annual doses. Such a
mechanism does not, however, explain why a single
dose should appear more effective than two or three
doses.
A possible explanation for the observed interac-
tion is that number of doses acts as a proxy for an-
other variable. If, for example, older individuals are
more likely than younger individuals to suffer non-
onchocercal visual field loss (e.g. because of glau-
coma or dense cataract), ivermectin would be
expected to have less overall impact among older age
groups - the very groups that received more doses
of ivermectin/placebo. The plausibility of such an
explanation is weakened, however, by our failure
to demonstrate any direct interaction between
ivermectin and age, sex, or any of the other variables
considered. A total of 21 of the individuals with
visual field deteriorations had cataracts at the end of
follow-up (12 in the ivermectin group and 9 in the
placebo group). Excluding such individuals from the
analysis gives an estimated rate ratio of 0.49 (95%
CI = 0.29, 0.81) for ivermectin versus placebo. The
interaction between ivermectin and number of doses
of ivermectin/placebo received is then no longer
statistically significant (P = 0.10). The estimated
rate ratios for one, two, and three doses, respectively,
are 0.11, 0.35, and 0.74. Similarly, if only individuals
with optic atrophy at baseline are considered, there
is no strong evidence that the impact of ivermectin
varies with the number of doses (P = 0.23).
In defining visual field deterioration, we chose a
largely arbitrary cut-off point (:19 spots lost in one
eye). The corresponds to a major change in visual
function. A strict cut-off point was chosen to ensure
a high specificity for our outcome measure. Indi-
rectly, the specificity can be assessed by examin-
ing the incidence of deteriorations according to the
number of Friedmann field analyses undergone by
individuals. If the outcome lacked specificity, the
number of deteriorations might have been expected
to decrease with the number of investigations as the
patient's performance improved. There was no evi-
dence that the incidence of visual field deteriorations
was lower among individuals who underwent four
analyses rather than only two (Table 1). An alterna-
tive indirect means of assessing specificity is to exam-
ine the effect of cut-off point, and for this purpose we
examined the following: -11 spots lost: -16 spots
lost; and ¢21 spots lost. At these cut-offs the ratio of
deterioration in the ivermectin group to that in the
placebo group was 0.87, 0.72, and 0.49, respectively
(at ¢19 spots the ratio was 0.59). These ratios indi-
cate that the specificity increased with the cut-off
point. Crude analysis of these cut-off points indicate
that the statistical significance of the impact of
ivermectin increased as the cut-off criterion became
stricter (P = 0.38, P = 0.07, P = 0.01, P = 0.002).
In summary, our findings indicate that annual
dosing with ivermectin substantially reduces the rate
of visual field loss in guinea savanna communities
that are mesoendemic for onchocerciasis. As far as
we are aware, this is the first report that ivermectin
has an impact on visual function, rather than eye
lesions; we have previously found that it has an im-
pact on the onset of onchocercal optic atrophy. In
the current study, the majority of cases of visual field
loss that were identified occurred in eyes with optic
atrophy at baseline. Thus, ivermectin appears to pre-
vent or delay the onset of optic atrophy and subse-
quently slow the progression of the disease, as
measured by visual field loss.
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Resume
Impact de I'administration annuelle
d'ivermectine sur l'evolution de la perte
de champ visuel due a l'onchocercose
Cet article decrit l'impact de l'ivermectine en traite-
ment annuel sur la perte de champ visuel, deter-
min6 lors d'un essai randomis6 en double aveugle
contre placebo. L'essai a ete realis6 dans 34
communautes rurales de l'Etat de Kaduna, dans
le nord du Nig6ria, ou l'onchocercose de savane
guineenne est mesoend6mique. L'exploration du
champ visuel paracentral a ete r6alis6e a l'aide d'un
appareil de Friedmann mark I au d6but de l'essai
puis au bout de 2 et 3 ans de suivi. Une perte
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absolue de .19 points sur un ceil pendant la
periode de suivi a ete prise comme seuil de
deterioration du champ visuel. Lors de l'examen
initial, 939 personnes ont vu .19 points avec au
moins un ceil et ont pu etre incluses dans l'etude;
l'examen du champ visuel a 6te repete pendant
le suivi chez 636 d'entre elles (68%). Les taux de
suivi ont ete similaires dans le groupe traite par
l'ivermectine et dans le groupe placebo (dur6e
moyenne = 28,3 mois), ces groupes etant bien
apparies en ce qui concerne l'age, le sexe, la
charge microfilarienne et l'etat initial du champ
visuel. Au total, 92 personnes (34 dans le groupe
ivermectine et 58 dans le groupe placebo) ont
pr6sente une deterioration du champ visuel. Le
rapport d'incidence corrige du groupe placebo etait
de 0,64 (intervalle de confiance a 95% = 0,42-
0,98). 11 semble que l'impact de l'ivermectine soit
plus grand chez les personnes qui ont requ une
seule dose que chez celles qui ont recu trois doses.
Une pathologie du nerf optique, seule ou associee a
une pathologie chorio-retinienne, a ete observ6e
chez plus de 90% des sujets ayant une deteriora-
tion du champ visuel. Alors que I'association de ces
deux pathologies 6tait courante chez ces sujets
(51%), une pathologie chorio-retinienne isolee n'a
ete observee que chez un seul sujet. La plupart des
d6t6riorations (75%) ont ete observees chez des
sujets ayant d6ja une atrophie optique au premier
examen. Une analyse limitee a ces cas a indiqu6
une diminution de 45% de l'incidence de la
det6rioration du champ visuel apres administration
d'ivermectine (intervalle de confiance a 95% = 8-
67%). Nous avions deja rapport6 un impact de
l'ivermectine sur l'incidence de l'atrophie optique
dans cette meme population. Les resultats de la
presente etude montrent que ce compose a aussi
un impact sensible sur la progression de la perte de
champ visuel chez les sujets deja atteints d'une
atrophie optique. 11 semble donc que l'ivermectine
empeche ou retarde I'apparition d'une telle atrophie
et ralentisse l'6volution de la maladie, mesurable
par examen du champ visuel. A notre connais-
sance, c'est la premiere fois qu'un impact de
l'ivermectine sur la fonction visuelle et non sur les
lesions oculaires est rapport6.
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